Metformin Aurovitas (Metformin Hydrochloride)

Metformin activates the enzyme AMP‑activated protein kinase (AMPK) in liver cells, which suppresses gluconeogenesis—the production of new glucose. It also enhances peripheral glucose uptake and improves insulin signaling, leading to reduced circulating glucose without stimulating insulin secretion.

The dosage of Metformin Aurovitas is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of Metformin during pregnancy or lactation should be evaluated by a qualified clinician. While some guidelines allow its use in certain pregnant patients with diabetes, the decision depends on risk‑benefit assessment. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metformin belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because it does not cause weight gain and has a low risk of hypoglycemia when used alone. Compared with sulfonylureas, it has a more favorable safety profile, and unlike insulin, it is administered orally.

Metformin Aurovitas should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and store them out of reach of children.

Metformin Aurovitas is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, excessive alcohol intake, or hypoxia. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin Aurovitas is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with conditions that predispose to hypoxia or severe infection.